Data / Form D filings / Variant Bio, Inc.
Variant Bio, Inc.: Form D filings
Variant Bio, Inc., a biotechnology company in Seattle, WA, filed 4 Form D notices with the SEC between 2019 and 2021. The latest, on November 17, 2021, reports $105 million sold of a $105 million offering to 12 investors.
Find out what Variant Bio, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1616 EASTLAKE AVE E, SUITE 208, Seattle, WA, 98102
- Phone
- (206) 719-6382
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2018
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1790599
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 17, 2021 | Amendment | $104,999,883 | $104,999,883 | $0 | 12 | Oct 29, 2021 | sec.gov |
| Nov 4, 2021 | New notice | $104,999,883 | $94,999,891 | $9,999,992 | 11 | Oct 29, 2021 | sec.gov |
| Aug 5, 2020 | New notice | $6,699,999 | $6,099,988 | $600,011 | 6 | Jul 28, 2020 | sec.gov |
| Oct 10, 2019 | New notice | $31,539,057 | $16,639,530 | $14,899,527 | 2 | Sep 27, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Stuart Nagae | Director | |
| Bob More | Director | |
| Andrew Farnum | Executive Officer, Director | |
| Elena Viboch | Director | |
| Josh Wolfe | Director | |
| Stephane Castel | Executive Officer, Director | |
| Julie Sunderland | Director |
Other biotechnology companies in Washington that filed recently
- Key Proteo, Inc. $2.3 million · Oct 23, 2026
- Inmedix, Inc. $4 million · Oct 22, 2026
- Q-Immune, Inc. $25,000 · Sep 28, 2026
- Hexamer Therapeutics, Inc $500,000 · Sep 15, 2026
- MalarVx, Inc. $125,000 · Aug 25, 2026
- Strella Biotechnology, Inc. $1.8 million · Aug 14, 2026
Every Form D from the week of Nov 15, 2021 · All recent filings in Washington · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Variant Bio, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.